Pattern one
The long-commute child
Two hours of travel daily, frequently spent on a phone at close range, with outdoor time squeezed out at both ends of the day.
There are three families of intervention with real evidence behind them, their effect sizes overlap substantially, and the right choice usually turns on cost and daily burden rather than on clinical superiority. Any clinic that only offers one will recommend that one. We set out all three with their trade-offs. For Mumbai families, with reviews that fit the week.
Head-to-head evidence does not identify one clearly superior intervention across all children, which is genuinely useful to know when comparing offers.
Low-dose atropine, peripheral-defocus optics and orthokeratology all show meaningful slowing of progression, with reported effect sizes that overlap considerably and vary between studies and populations. There is no strong basis for declaring a single winner, and combination approaches are an area of ongoing study rather than settled practice.
What differs sharply between them is practical: nightly drops versus full-time lens wear versus overnight rigid lenses; a low recurring cost versus a high one; independence from spectacles versus dependence on consistent wear. Those differences determine adherence, and adherence determines the outcome far more than the small differences in reported efficacy.
A practice fitting only orthokeratology will recommend orthokeratology; one dispensing only defocus spectacles will recommend those. It is not dishonesty, it is availability. Asking which options a provider does not offer is a fast way to understand the shape of the advice you are being given.
A myopic child on stable, slow progression may need monitoring rather than intervention. The rate is what distinguishes the two groups.
Consultation and six-monthly progression review, with biometry arranged locally and the readings interpreted with you.
First appointment
Baseline refraction and history completed in a single appointment, with the axial length measurement specified so it can be arranged locally without a second consultation.
Prescription check
Accurate full correction confirmed at once, because the most common finding at intake here is a prescription eighteen months old in a child who has progressed since.
Weekly work
The control option chosen for what a compressed family schedule can actually sustain, since an approach abandoned after three months achieves nothing whatever its trial data.
Review and step down
Six-monthly review kept short and specific: two measures, compared with the last two, and an explicit decision to continue or change.
Mumbai and the MMR
Six-monthly review is a modest commitment on paper and still needs to be practical, which in this city means minimising the number of in-person visits.
Pattern one
Two hours of travel daily, frequently spent on a phone at close range, with outdoor time squeezed out at both ends of the day.
Pattern two
Months of indoor time under artificial light, with near-work demand high and daylight exposure minimal.
Pattern three
Both parents significantly myopic and aware of the trajectory. Usually the group most willing to start early and most consistent afterwards.
Across Mumbai and the MMR we hear from families in
We coordinate with a local optometrist for biometry and dispensing rather than duplicating what is already available near you.
Not a bad sign, just an incomplete picture. Orthokeratology is a legitimate, well-evidenced option and a practice that fits it well may be an excellent choice for your child. What you are missing is a comparison: whether nightly atropine at a fraction of the cost, or defocus spectacles with far lower daily burden, would achieve something similar in your child’s case. That comparison is what we would provide, and if orthokeratology still comes out best we will say so.
Two things are happening and only one gets discussed. The near-work load is real: a phone at twenty-five centimetres is a much higher demand than a book at forty. Arguably more important is what those hours displace — that is four hours of the day unavailable for outdoor exposure, and the outdoor evidence is the more consistent of the two. Larger text, greater viewing distance, and deliberate distance viewing during the journey are all achievable, and they are worth more than they sound.
Typically two in-person visits a year for biometry and any lens review, plus one or two short remote consultations to go through the numbers and adjust the plan. That is a deliberately low in-person count, because six-monthly cross-city travel is exactly the kind of commitment that quietly lapses. If your child is on orthokeratology the in-person requirement is higher, and we would factor that into the choice rather than discovering it later.
The newer designs, which place defocus segments in the periphery while keeping the central zone clear, have produced encouraging multi-year results and are a reasonable first option for many children. They are less demanding than contact lenses and carry no infection risk, which matters for younger children. Effectiveness varies between designs and between individuals, so the important part is measuring whether it is working in your child rather than assuming.
As soon as progressive myopia is identified, because the highest progression rates occur in the youngest children and the earlier onset is, the higher the eventual endpoint tends to be. A child becoming myopic at seven faces a longer progression period than one becoming myopic at thirteen, and is the higher priority for intervention. Waiting to see how fast it progresses costs exactly the period in which intervention is most valuable.
Move a slider to blur a classroom, playground or park the way a myopic child would see it. A free, 60-second way to understand why your child squints, sits close to the TV, or complains of headaches after school.
Two Clinics · Seven Telehealth Cities
Consultation for Mumbai by secure telehealth — in-clinic biometry in Chennai and Hyderabad.
It is the fastest way to understand the advice you are being given. We compare all three on effect size, cost and daily burden before recommending one.